These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26101172)

  • 1. A mechanism for mineralocortcoid participation in renal disease and heart failure.
    Re RN
    J Am Soc Hypertens; 2015 Aug; 9(8):586-91. PubMed ID: 26101172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 3. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
    Pende A; Montecucco F
    Curr Pharm Des; 2012; 18(7):950-1. PubMed ID: 22283769
    [No Abstract]   [Full Text] [Related]  

  • 6. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renoprotective treatments : renin-angiotensin-aldosterone system blockade and beyond].
    Esnault V
    Rev Prat; 2024 Jun; 74(6):s19-s22. PubMed ID: 39011717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Expanded View of Progressive Cardiorenal Disorders.
    Re RN
    Am J Med Sci; 2016 Jun; 351(6):626-33. PubMed ID: 27238929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novelties in Therapy of Chronic Heart Failure.
    Doimo S; Pavan D
    Heart Fail Clin; 2021 Apr; 17(2):255-262. PubMed ID: 33673949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL; Clark D; Calhoun DA; Ahmed MI
    Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.
    Valluri A; Struthers AD; Lang CC
    Curr Heart Fail Rep; 2014 Mar; 11(1):31-9. PubMed ID: 24234398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Salt-induced inappropriate augmentation of intrarenal RAAS and its treatment in patients with chronic kidney disease].
    Konishi Y
    Nihon Rinsho; 2012 Sep; 70(9):1588-92. PubMed ID: 23012808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure.
    McCullough PA; Rangaswami J
    Nephron; 2018; 138(3):173-175. PubMed ID: 29207385
    [No Abstract]   [Full Text] [Related]  

  • 18. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure therapy: what should clinicians believe?
    Fang JC
    JAMA; 2012 Nov; 308(20):2144-6. PubMed ID: 23188032
    [No Abstract]   [Full Text] [Related]  

  • 20. A possible mechanism for the progression of chronic renal disease and congestive heart failure.
    Re RN
    J Am Soc Hypertens; 2015 Jan; 9(1):54-63. PubMed ID: 25539896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.